Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.

Some people have low sulfotransferase enzyme levels, affecting their response to minoxidil. Lifestyle factors, genetics, and diet, like MSM intake, might influence these enzyme levels.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

A user is asking if a new hair product, Cypress Premium Vials Energy and Cypress Premium Shampoo Energy, could be dangerous or worsen their hair condition. The product contains various ingredients including water, alcohol, menthyl lactate, and several extracts.

The conversation discusses changes in scalp texture and appearance in areas of hair loss, with concerns about the suitability of these areas for hair transplants. Users mention issues like fibrosis, inflammation, and thinner skin, advising caution and consultation with clinics before proceeding with transplants.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

The conversation is about the use and application of CB-03-01-2 (Breezula) for hair loss, including questions about its form, how to apply it, and the duration 10g would last. Specific treatments discussed are Minoxidil, finasteride, and RU58841.

Poor sleep quality may affect hair growth cycles by disrupting the body's natural clock and stress hormones. The focus should be on improving sleep to support overall health, including hair growth, rather than relying solely on treatments like Minoxidil, finasteride, or RU58841.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

The conversation is about a user planning a blood test to monitor health while on hair loss treatments: Finasteride, Minoxidil, and Dutasteride. Recommendations include testing for androgens, thyroid function, micronutrients, and basic health markers, with additional suggestions for PSA, prolactin, and estradiol.

The conversation discusses exploring new hair loss treatments beyond popular ones like Finasteride, Minoxidil, and Ketoconazole. Specific treatments mentioned include ozone therapy, Dutasteride mesotherapy, RegeneraActiva, microcurrent electrical hair stimulation, Nourkrin, and BioEqua Enercharger.

The post discusses the experiences of individuals with diffuse hair thinning using finasteride, with many reporting no improvement or worsening conditions after 6 months. Various suggestions include persisting with the treatment, checking for underlying conditions, adding minoxidil for volume, adjusting dosage, and considering other potential causes like autoimmune responses and inflammation.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

The user is seeking advice on improving their hair loss treatment regimen, considering changes to their topical solution, and is curious about others' daily routines and recommendations for medications and supplements. They are contemplating switching Tretinoin for Tazarotene, Latanoprost for Bimatoprost, and possibly adding Alfatradiol, Topical Melatonin, or a topical androgen receptor antagonist.

After 4 months of using topical finasteride and minoxidil, blood tests showed increased E2, Test, and Prolactine levels. The user is concerned about potential side effects like gyno and is seeking advice on managing these values.

Using vitamin C in shampoo to adjust pH levels can improve hair health and reduce oiliness and dandruff. The user mixed vitamin C powder with conditioner, achieving positive results.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.

The user is experiencing low libido and mood swings after starting a low dose of topical finasteride. They are considering further blood tests to investigate low testosterone levels and other hormonal factors.

The conversation is about a hair loss treatment regimen that includes finasteride, dutasteride, oral minoxidil, Dermapen, quercetin, N-acetyl L-cysteine, biotin, millet seed extract, MSM, OPC, green tea extract, high-dose vitamins B1-B12, boron, and silica. The user is seeking advice on additional treatments.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

Switching from topical to oral minoxidil resolved issues like watery eyes and ear itchiness. Users report oral minoxidil is better for sensitive skin, though some are concerned about side effects like hair growth everywhere.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.